Oramed Pharmaceuticals, Inc. (ORMP) is higher by Monday morning, with the stock rising 1.54% in pre-market trading to 3.3. ORMP's short-term technical score of 56 indicates that the stock has traded more bullishly over the last month than 56% of stocks on the market. In the Biotechnology industry, which ranks 109 out of 146 industries, the stock ranks higher than 69% of stocks. Oramed Pharmaceuticals, Inc. has fallen 17.93% over the past month, closing at $4.02 on May 29. During this period of time, the stock fell as low as $3.25 and as high as $4.36. ORMP has an average analyst recommendation of Sell. The company has an average price target of $3.65.
ORMP has an Overall Score of 48. Find out what this means to you and get the rest of the rankings on ORMP!